ABBV Stock Overview
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 1/6 |
Financial Health | 3/6 |
Dividends | 4/6 |
Rewards
Risk Analysis
+ 1 more risk
AbbVie Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$155.92 |
52 Week High | US$168.66 |
52 Week Low | US$119.50 |
Beta | 0.56 |
1 Month Change | -5.45% |
3 Month Change | 3.26% |
1 Year Change | 6.00% |
3 Year Change | 69.20% |
5 Year Change | 122.71% |
Change since IPO | 86.42% |
Recent News & Updates
Recent updates
Shareholder Returns
ABBV | AT Biotechs | AT Market | |
---|---|---|---|
7D | -0.6% | -2.6% | -0.3% |
1Y | 6.0% | -12.3% | 2.4% |
Return vs Industry: ABBV exceeded the Austrian Biotechs industry which returned -12.4% over the past year.
Return vs Market: ABBV exceeded the Austrian Market which returned 1.8% over the past year.
Price Volatility
ABBV volatility | |
---|---|
ABBV Average Weekly Movement | 2.3% |
Biotechs Industry Average Movement | 7.6% |
Market Average Movement | 3.4% |
10% most volatile stocks in AT Market | 5.4% |
10% least volatile stocks in AT Market | 1.6% |
Stable Share Price: ABBV has not had significant price volatility in the past 3 months.
Volatility Over Time: ABBV's weekly volatility (2%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 50,000 | Rick Gonzalez | www.abbvie.com |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine.
AbbVie Inc. Fundamentals Summary
ABBV fundamental statistics | |
---|---|
Market cap | €273.23b |
Earnings (TTM) | €4.53b |
Revenue (TTM) | €51.03b |
60.5x
P/E Ratio5.4x
P/S RatioIs ABBV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ABBV income statement (TTM) | |
---|---|
Revenue | US$54.32b |
Cost of Revenue | US$16.73b |
Gross Profit | US$37.59b |
Other Expenses | US$32.77b |
Earnings | US$4.82b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 26, 2024
Earnings per share (EPS) | 2.72 |
Gross Margin | 69.21% |
Net Profit Margin | 8.87% |
Debt/Equity Ratio | 573.6% |
How did ABBV perform over the long term?
See historical performance and comparison